Preclinical data has supported Ang (1-7) and AT2 agonists as viable treatment targets, but whether they are effective therapeutic targets in hypertension, cardiovascular and kidney diseases remains to be confirmed in clinical trials (112–114). Here, AGTR2 is linked to kidney disorder.